Background. Increased levels of macrolide-resistant Streptococcus pyogenes in focal regions of the United States have been reported. The purpose of this study was to determine the antimicrobial susceptibility of a large collection of S. pyogenes isolates from throughout the United States and to elucidate the mechanisms of resistance and genetic relatedness of macrolide-resistant isolates.
to macrolides has emerged in this organism. Elevated rates of macrolide resistance (125%) among S. pyogenes reported in Korea [2] , Taiwan [3] , Spain [4, 5] , and Italy [4] are causes of concern. Limited surveillance data suggest that the overall rate of macrolide-resistant S. pyogenes in the United States is 3%-9% [6] [7] [8] . Higher rates of macrolide resistance among S. pyogenes have been noted in some US communities [9] [10] [11] .
There are 2 primary mechanisms of macrolide resistance in S. pyogenes: efflux (encoded by mefA) [12] and target modification due to ribosomal methylation (encoded by ermB or ermA) [13, 14] . Isolates with the mefA gene have a pattern of resistance known as the M phenotype: they are macrolide resistant but lincosamide and streptogramin B susceptible [12] . S. pyogenes isolates with the ermB gene are usually resistant to macrolides, lincosamides, and streptogramin B antibi- otics-a resistance pattern known as "constitutive MLS B " [14] .
Isolates with the ermA gene typically have an inducible MLS B phenotype that requires exposure to a macrolide inducer before clindamycin resistance becomes evident [13, 14] . There are rare reports of L4 ribosomal protein and 23S rRNA mutations in macrolide-resistant S. pyogenes isolates [8, 15, 16] . An understanding of the emergence of antimicrobial resistance in S. pyogenes is important for vaccine and new antimicrobial development. The purpose of this study was to determine the antimicrobial susceptibility of a large collection of S. pyogenes clinical isolates from the United States and to elucidate the mechanisms of resistance and genetic relatedness of macrolide-resistant S. pyogenes isolates.
METHODS

Isolates.
Isolates of S. pyogenes that caused clinical infection during the period of November 2002 through April 2003 were sent to the University of Iowa (Iowa City) from 45 medical centers in the United States. The surveillance program included consecutive isolates from unique patients recovered from cultures submitted to the medical centers as part of routine patient care. The 1885 S. pyogenes isolates obtained were from 9 regions (New England, Middle Atlantic, South Atlantic, East North Central, East South Central, West North Central, West South Central, Mountain, and Pacific regions). The identification of the isolates was confirmed by b-hemolysis and a positive pyrrolidonyl aminopeptidase (PYR) test result [17] . The isolates were stored at Ϫ70ЊC.
Susceptibility testing. Susceptibility testing was performed using a broth microdilution method in Mueller-Hinton broth supplemented with 3% lysed horse blood, in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines [18] . The antimicrobial agents tested were penicillin, cefdinir, erythromycin, azithromycin, clarithromycin, clindamycin, telithromycin, and levofloxacin. CLSI MIC interpretive criteria for "Streptococcus spp. other than S. pneumoniae" were used if available; for telithromycin and cefdinir, S. pneumoniae breakpoints were applied [19] . Quality-control testing was performed with S. pneumoniae ATCC 49619.
Macrolide resistance phenotype. The double-disk diffusion test (D-zone test) was performed with erythromycin-resistant isolates using 15-mg erythromycin disks and 2-mg clindamycin disks placed 16 mm apart, as described elsewhere [9, 19, 20] . Isolates with blunting of the inhibition zone around the clindamycin disk adjacent to the erythromycin disk were considered to be inducible MLS B phenotype. Clindamycin-susceptible isolates without blunting were considered to be M phenotype. Isolates that were resistant to erythromycin and clindamycin were considered to be constitutive MLS B phenotype.
Resistance gene detection. A multiplex PCR for ermA, ermB, and mefA was performed on all macrolide-resistant isolates. Isolates were grown on 5% sheep blood agar for 18-24 h. One loopful of bacteria suspended in 100 mL of lysis buffer was heated to 100ЊC for 10 min and cooled at room temperature for 15 min. After centrifugation at 13000-16000 g for 30-60 s, the supernatant was saved for PCR. The primers used had been published previously, as follows: mefA, 5 -AGT ATC ATT AAT CAC TAG TGC-3 and 5 -TTC TTC TGG TAC TAA AAG TGG-3 [21] ; ermA, 5 -GCA TGA CAT AAA CCT TCA-3 and 5 -AGG TTA TAA TGA AAC AGA-3 ; and ermB, 5 -CGA GTG AAA AAG TAC TCA ACC-3 and 5 -GGC GTG TTT CAT TGC TTG ATG-3 [22] . Previously published thermal cycler conditions were used [22] . Amplification products were separated by electrophoresis on 1% agarose gels (175V for 60-90 min) and were stained with ethidium bromide. The presence of a gene was determined by comparison with positive control strains yielding the expected product size of 206, 616, and 348 bp for ermA, ermB, and mefA, respectively. The following positive control strains were kindly provided by Abbott Laboratories: S. pyogenes 8084 (mefA), S. pyogenes 609 (ermA), S. pyogenes 6945 (ermB). Mutation analysis of L4 and L22 ribosomal protein and 23S rRNA genes was performed on all macrolide-resistant isolates that were negative for ermA, ermB, and mefA by previously described methods [8, 16, 23] . Quinolone resistance-determining region mutation analysis was performed on all fluoroquinolone-resistant isolates, as described elsewhere [24] .
PFGE. All macrolide-resistant isolates and all isolates recovered from sterile sites were characterized by PFGE after DNA digestion with ApaI (New England Biolabs) using CHEF-DR II (Bio-Rad) at 14ЊC and 200V for 23 h (initial forward time, 1 s; final forward time, 17 s). Gels were stained with ethidium bromide and analyzed using Bionumerics software (Applied Maths). The unweighted pair group method with arithmetic averages and the DICE coefficient (1.0% optimization, 1.0% position tolerance) were used to construct a dendrogram. Isolates were assigned to the same PFGE pattern if their profile differed by no more than 3 bands (i.e., a similarity coefficient of у85% on the dendrogram) [25] .
emm Typing. The emm type of all macrolide-resistant isolates and isolates recovered from all sterile sites was determined by amplification and sequencing of the M protein gene (emm) at Wake Forest University (Winston-Salem, NC) according to the protocol at the Streptococcus pyogenes emm sequence database (at http://www.cdc.gov/ncidod/biotech/strep/protocols .htm). The assignment of emm types and subtypes was as described at the "Assigning emm Types and Subtypes" section of that database (at http://www.cdc.gov/ncidod/biotech/strep/ assigning.htm).
RESULTS
Resistance was detected to erythromycin (6.8% of isolates), azithromycin (6.9%), clarithromycin (6.6%), clindamycin (0.5%), telithromycin (0.2%), and levofloxacin (0.05%) (table 1). The only levofloxacin-resistant isolate (MIC, 16 mg/mL) was found to have a mutation in gyrA (Glu85rGly) and parC (Ser79rPhe).
A significantly higher portion of macrolide-resistant isolates were detected among patients from the 15-24-year-old and 25-34-year-old age groups, whereas a lower rate of macrolide resistance was noted among isolates from patients aged 5-14 years (table 2). The majority of isolates were pharyngeal (85%), and the rate of macrolide resistance noted among these isolates (6.2%) was significantly lower than that for isolates from other sites (table 2). The higher rate of erythromycin resistance among lower respiratory tract isolates (21.9%) also reached statistical significance.
The geographic source of the isolates and macrolide-resistance phenotypes are shown in The 4 isolates that were resistant to the new ketolide telithromycin all had constitutive MLS B phenotype (3 with ermB and 1 with an A2058G 23S rRNA mutation). The emm types of the telithromycin-resistant isolates were emm73 (2 isolates), emm96, and emm12.7; none were found to be closely related by PFGE (i.e., they had unique patterns). The 4 isolates were from throat cultures collected from different medical centers in 3 regions (Pacific, West North Central, and Middle Atlantic). The genetic diversity of the 66 isolates recovered from sterile sites was demonstrated by their assignment to 34 different PFGE patterns (table 7); 14 of the PFGE patterns were shared with macrolide-resistant isolates (table 6). Only PFGE pattern R contained macrolide-resistant and macrolide-susceptible isolates recovered from sterile sites. The largest clusters of sterile site isolates contained 5 or 6 isolates (PFGE patterns N, Q, and R).
DISCUSSION
The susceptibility to penicillin of all isolates in the current study validates the practice of using this drug as first-line therapy for S. pyogenes infection [26] and for not performing routine in vitro susceptibility testing unless a patient is allergic to b-lac- tams. The continued susceptibility of S. pyogenes to b-lactams is remarkable, especially when compared with the emergence of resistance to b-lactams among pneumococci over the past decade. A limited ability to acquire foreign DNA and a physiologic fitness cost associated with b-lactam resistance are possible explanations for this organism's continued susceptibility to penicillin [27] .
To the best of our knowledge, the current study (with 1885 isolates obtained from 45 medical centers) is the largest multicenter S. pyogenes surveillance study that has been performed in the United States to date. The erythromycin resistance rate of 6.8% detected in this study is higher than the 1% rate noted among 764 US isolates from 1992-1993 [28] and the 2.6% rate reported among 301 US isolates from 1994-1997 [6] , but it is similar to the 8.6% rate reported by a 2001 North American study that tested 397 isolates [7] . A prospective, communitybased US study that recovered 1057 pharyngitis isolates from 3-18-year-old patients in 2002-2003 [8] included cultures from antigen-positive cases, yet it reported a macrolide-resistance rate of 3.8%, which is similar to the 5% rates noted for subjects aged 0-4 and 5-14 years in the present study. Studies from the United States that have focused on small geographic regions have detected higher levels of macrolide resistance for discrete periods of time, suggesting that the macrolide susceptibility of a single S. pyogenes isolate may not be reliably predicted without in vitro testing [9] [10] [11] .
The reason for the higher macrolide resistance rates noted among isolates from a particular age group (15-34-year-old persons), specimen source (lower respiratory tract), and region (Pacific) in the present study is not clear. The experience from Finland supports the speculation that a higher level of macrolide exposure could be a contributing factor [29] .
Our data suggest the population of macrolide-resistant S. pyogenes isolates in the United States comprises similar proportions of isolates containing mefA (43%) and ermA (46%), with a smaller fraction of isolates having ermB (8.5%) and considerable variation among regions. Surveillance from other countries shows varied predominance of a particular resistance genotype among macrolide-resistant isolates: mefA in Spain (97% of 437 isolates) [30] , Belgium (84% of 131 isolates) [31] , Germany (56% of 54 isolates) [32] , and Ontario, Canada (92% of 72 isolates) [33] ; and ermB in France (55% of 93 isolates) [22] .
The expression of an M phenotype in every isolate with mefA was as expected; however, the ermB isolate with an M rather than MLS B phenotype is unusual (table 4). The inducible MLS B phenotype was highly predictive (92%) of the presence of ermA. The genetic change mediating a constitutive MLS B phenotype cannot be reliably predicted (45% had ermB, 27% had ermA, and 27% had a 23S rRNA mutation).
The large proportion of isolates with the inducible MLS B phenotype supports the new 2005 CLSI recommendation to perform the D-zone test on macrolide-resistant isolates of bhemolytic streptococci to determine clindamycin susceptibility [19] . Because this is a new recommendation, clinicians should be sure that microbiology laboratories are screening for inducible clindamycin resistance before accepting a report of "clindamycin susceptible" for a macrolide-resistant S. pyogenes isolate.
This appears to be only the third report of 23S rRNA mutations in macrolide-resistant S. pyogenes isolates. A C2611U mutation (domain V) in 23S rRNA was reported in an azithromycin-resistant S. pyogenes isolate (MIC, 2 mg/mL) obtained from the throat of a patient in Croatia [15] . The A2058G and A2059G 23S rRNA mutations detected in 3 isolates in the present study were also recently reported among 3 of 118 macrolide-resistant S. pyogenes isolates collected during 2000-2003 [8] . All 6 of these isolates with A2058G or A2059G 23S rRNA mutations from the 2 studies expressed different emm types but the same cMLS B phenotype [8] .
The identification of 4 major clones (PFGE patterns A-D), each associated with a predominant emm type and resistance genotype (emm75/mefA, emm58/ermA, emm12/ermA, and emm114/ermA), representing 51% of the erythromycin-resistant isolates in this study (table 6) , is consistent with local reports of increased resistance associated with a predominant clone. In 2000-2001, an outbreak of erythromycin-resistant S. pyogenes infection was attributed to a single emm6/mefA strain in a Pittsburgh, Pennsylvania, school [9] . In a 2-month period during 2002, 87% of 47 erythromycin-resistant isolates in southwestern Pennsylvania belonged to an emm75/mefA clone [11] -this may be the same PFGE A clone that accounted for 22% of the 129 erythromycin-resistant isolates in the present study.
Studies from other countries have also revealed a few clones that constitute a large portion of the population of macrolideresistant S. pyogenes isolates [30, 32] . Among 437 erythromycinresistant Spanish isolates from 1988-1997, a total of 79% belonged to 2 clones (emm4/mefA and emm75/mefA) [30] . Among 54 erythromycin-resistant German isolates from 1999-2000, a total of 52% clustered in 3 clonal groups (emm4/mefA, emm77/ ermA, and emm12/mefA) [32] .
The 3 telithromycin-resistant isolates with ermB (MIC, у16 mg/mL) are consistent with reports associating ermB in S. pyogenes isolates with poor telithromycin activity [32, 34, 35] . The fourth telithromycin-resistant isolate in the current study had a lower MIC (4 mg/mL) and a 23S rRNA A2058G mutation not previously associated with decreased telithromycin activity.
The rate of macrolide resistance among sterile-site isolates was not statistically different from that for all other specimen types. Overall, the sterile-site isolates were more genetically diverse (66 isolates with 34 PFGE patterns) than the macrolideresistant isolates (129 isolates with 28 PFGE patterns). The 4 most common emm types among sterile-site isolates were types emm1, emm3, emm12, and emm28 that represented 45.4% of isolates. This is similar to surveillance data from the Centers for Disease Control and Prevention for 1995-1999 and 2000-2001 that reported that the same 4 emm types were predominant, constituting 44.7% of 1586 and 44.8% of 1064 invasive isolates, respectively [36, 37] .
The prevalence of the 3 most common emm types among macrolide-resistant throat isolates in the current study was higher than the prevalence among 1975 pediatric pharyngeal isolates from North America in 2000-2002 (macrolide susceptibility was unknown) [38] : emm75 (25.2% vs. 3.8%), emm12 (20.2% vs. 18.4%), and emm58 (14.1% vs. 0.4%). Among 120 macrolide-resistant pediatric throat isolates from the United States from 2000-2003, the same 2 emm types that were predominant in the current study were also the most common: emm12 (27.5% of isolates) and emm75 (21.7%) [8] .
The only fluoroquinolone-resistant isolate detected was recovered from a blood culture and was susceptible to the other antimicrobials tested. The isolate was emm5.23 and shared a PFGE pattern with 2 emm5.14 sterile site isolates. The detection of only a single fluoroquinolone-resistant isolate is reassuring and consistent with the rare reports of this type of resistance [24, 39, 40] . The parC (Ser79rPhe) mutation has previously been associated with fluoroquinolone resistance in S. pyogenes [24, 40] . The Glu-85rGly gyrA mutation has been identified among levofloxacin-resistant pneumococcal isolates [41] .
Our findings suggest that the overall population of macrolide-resistant S. pyogenes in the United States is small but includes several large clones with potential for expansion. In vitro testing of S. pyogenes isolates for macrolide susceptibility is warranted for patients who are allergic to b-lactams. The high percentage of macrolide-resistant S. pyogenes isolates with the inducible MLS B phenotype (47%) supports the new CLSI recommendation for D-zone testing to detect inducible clindamycin resistance in this population. Longitudinal surveillance studies are needed to determine the stability of the trends reported above and to guide therapy and vaccine development strategies.
